Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated
A. Torres-Flores, L. A. Ontiveros-Padilla, R. L. Madera-Sandoval, A. Tepale-Segura, J. Gajon-Martinez, T. Rivera-Hernandez, E. A. Ferat-Osorio, A. Cerbulo-Vazquez, L. A. Arriaga-Pizano, L. Bonifaz, G. Paz-De la Rosa, O. Rojas-Martinez, A. Suarez-Martinez, G. Peralta-Sanchez, D. Sarfati-Mizrahi, , C. Lopez-Macias
This paper evaluates the AVX/COVID-12 vaccine's ability to activate T cells and bind antibodies from vaccinated individuals and SARS-CoV-2-infected patients.
bioRxiv · Mar 1, 2024 · PreprintImmunology